Atlas Trials

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Clinical trial NCT06431490 · RECRUITING

Trial details

NCT number
NCT06431490
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Biliary Tract Cancer
Start date
2024-07-22
Primary completion
2027-05-01
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.